- Aptose Biosciences (NASDAQ:APTO): Q1 GAAP EPS of -$0.18 misses by $0.01.
- Total cash and cash equivalents and investments as of March 31, 2021 were $112.1 million. Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into the first half of 2023.
- Press Release